Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/978-3-030-63761-3_36 http://scihub22266oqcxt.onion/10.1007/978-3-030-63761-3_36 33973204!ä!33973204 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Adv+Exp+Med+Biol 2021 ; 1318 (ä): 657-672 Nephropedia Template TP {{tp|p=33973204|t=2021. Challenges of Cellular Therapy During the COVID-19 Pandemic |pdf=|usr=}}{{33973204}} gab.com Text Challenges of Cellular Therapy During the COVID-19 Pandemic JO: Adv Exp Med Biol http://www.kidney.de/pget.php?&tw=1&pmid=33973204 #FOAvip Currently, coronavirus disease 2019 (COVID-19) has spread worldwide and continues to rise. There remains a significant unmet need for patients with hematological malignancies requiring specialized procedures and treatments, like cellular therapy to treat or cure their disease. For instance, chimeric antigen receptor T (CAR-T) cell therapy is approved for relapsed/refractory (after two or more lines of therapy) diffuse large B cell lymphoma and B cell acute lymphoblastic leukemia that is refractory or in the second relapse in patients younger than 25 years of age. Similarly, hematopoietic stem cell transplantation (HSCT) can be a lifesaving procedure for many patients, such as those with acute myeloid leukemia with high-risk cytogenetics. Unfortunately, the COVID-19 pandemic has thrust upon the hematologists and transplant specialists' unique challenges with the implementation and management of cellular therapy. One of the significant concerns regarding this immunocompromised patient population is the significant risk of acquiring SARS-CoV-2 infection due to its highly contagious nature. Experts have recommended that if medically indicated, especially in high-risk disease (where chemotherapy is unlikely to work), these lifesaving procedures should not be delayed even during the COVID-19 pandemic. However, proceeding with CAR-T cell therapy and HSCT during the pandemic is a considerable task and requires dedication from the transplant team and buy-in from the patients and their family or support system. Open conversations should be held with the patients about the risks involved in undergoing cellular therapies during current times and the associated future uncertainties. Twit Text FOAVip Challenges of Cellular Therapy During the COVID-19 Pandemic ????Adv Exp Med Biol http://www.kidney.de/pget.php?&tw=1&pmid=33973204 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33973204 #FOAvip English Wikipedia <ref>{{Cite pmid|33973204}}</ref> Challenges of Cellular Therapy During the COVID-19 Pandemic #MMPMID33973204 Sahu KK; Ailawadhi S; Malvik N; Cerny J Adv Exp Med Biol 2021[]; 1318 (ä): 657-672 PMID33973204show ga Currently, coronavirus disease 2019 (COVID-19) has spread worldwide and continues to rise. There remains a significant unmet need for patients with hematological malignancies requiring specialized procedures and treatments, like cellular therapy to treat or cure their disease. For instance, chimeric antigen receptor T (CAR-T) cell therapy is approved for relapsed/refractory (after two or more lines of therapy) diffuse large B cell lymphoma and B cell acute lymphoblastic leukemia that is refractory or in the second relapse in patients younger than 25 years of age. Similarly, hematopoietic stem cell transplantation (HSCT) can be a lifesaving procedure for many patients, such as those with acute myeloid leukemia with high-risk cytogenetics. Unfortunately, the COVID-19 pandemic has thrust upon the hematologists and transplant specialists' unique challenges with the implementation and management of cellular therapy. One of the significant concerns regarding this immunocompromised patient population is the significant risk of acquiring SARS-CoV-2 infection due to its highly contagious nature. Experts have recommended that if medically indicated, especially in high-risk disease (where chemotherapy is unlikely to work), these lifesaving procedures should not be delayed even during the COVID-19 pandemic. However, proceeding with CAR-T cell therapy and HSCT during the pandemic is a considerable task and requires dedication from the transplant team and buy-in from the patients and their family or support system. Open conversations should be held with the patients about the risks involved in undergoing cellular therapies during current times and the associated future uncertainties. |*COVID-19[MESH] |*Hematopoietic Stem Cell Transplantation[MESH] |Cell- and Tissue-Based Therapy[MESH] |Humans[MESH] |Immunotherapy, Adoptive[MESH] |Pandemics[MESH]Challenges of Cellular Therapy During the COVID-19 Pandemic (epmc).pdf DeepDyve Pubget Overpricing